Pimicotinib

匹米替尼

Report date: 2026/04/17 20:02:02
NME

Base Information

Drug NamePimicotinib
Drug Alias Name盐酸匹米替尼贝捷迈ABSK-021
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionColony stimulating factor 1 receptor inhibitors
TargetsColony stimulating factor 1 receptor
Therapy Area/IndicationsSolid tumoursGraft vs Host DiseaseAmyotrophic Lateral Sclerosis +[10] 
Global Approved IndicationsGiant Cell Tumor of Tendon Sheath
Approved Indications in ChinaGiant Cell Tumor of Tendon Sheath
Original Approved Country/TerritoryMainland China
Original Approved Date2025/12/16
Country/TerritoryCanadaUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyABbisko Therapeutics Co LtdMerck KGaA, Darmstadt, Germany +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursGraft vs Host DiseaseAmyotrophic Lateral Sclerosis +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A